Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Charting Emerging Markets: J&J Growth Rates

This article was originally published in PharmAsia News

Executive Summary

PharmAsia News takes a closer look at J&J’s growth in key emerging markets.

You may also be interested in...



J&J’s Solid Launches Lead Strong Pharma Segment Quarter

Johnson & Johnson’s pharma unit posted strong sales growth in immunology and infectious disease, while its burgeoning oncology business is growing substantially.

J&J Doubles Down On Orthopedics With Synthes Deal; Takes Lead In Trauma

Johnson & Johnson will control a majority of the orthopedic trauma device market and double its stake in the spinal device field by acquiring Synthes for $21.3 billion under a definitive agreement announced April 27.

Asia Spotlight: China Eclipses Japan To Become Second Largest Pharma Market

Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC084888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel